Abstract：Objective：ToobservetheclinicaleffectofmodifiedMaxingShigantangforwind-warmthandlungheat diseasewithphlegm-heatobstructingthelungsyndromeanditseffectoncystatinC(CysC)andneutrophilalkaline phosphatase(NAP)inserum. Methods：Atotalof 115 casesofpatientswithwind-warmthandlungheatdiseasewith phlegm-heatobstructingthelungsyndromeweredividedintothestudygroupandthecontrolgroupaccordingtotherandom numbertablemethod， 58 and 57 casesineachgrouprespectively.Thecontrolgroupwasgivenroutinesymptomatic treatment，andthestudygroupwasadditionallytreatedwithmodifiedMaxingShigantangbasedonthetreatmentofthe controlgroup.Bothgroupsweretreatedforsevendays.ThelevelsofCysCinserumandthescoresofNAPbeforeandafter treatmentaswellastheclinicaleffectinthetwogroupswerecompared.Theadversereactionsinthetwogroupswere recorded. Results：Thetotaleffectiveratewas 96.55%inthestudygroup，higherthanthatof 84.21%inthecontrolgroup， thedifferencebeingsignificant(P＜0.05).Aftertreatment，thelevelofCysCinserumandtheNAPscoreinthestudygroup weresignificantlylowerthanthoseinthecontrolgroup，differencesbeingsignificant(P＜0.05).Therewasonecaseofpatient whowaswithsymptomsofdiarrheaandrelievedbyhimselfinthestudygroup，andtherewasnoadversereactioninthe controlgroup. Conclusion：ModifiedMaxingShigantanghasgoodcurativeeffectintreatingwind-warmthandlungheat diseasewithphlegm-heatobstructingthelungsyndrome，whichcansignificantlyreducethelevelsofserumCysCandNAP inpatientswithhighsafety.